Company: SXTPW
Filing Date: 2025-02-06
Form Type: 424B5
Source: 0001213900-25-010772
Chunk: 5

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-06
Form: 424B5
Chunk 5
---
 travel was substantially impacted by the pandemic, we did not undertake any active marketing efforts for Arakoda. Following our recent financing the Company hired a Chief Commercial Officer and commissioned IQVIA market data and a qualitative marketing demand study. That research, recently completed, suggests that prescribing for malaria prevention therapies has returned to pre-pandemic levels, and that the total U.S. market represents around 1.1 million prescriptions (one prescription per three weeks of travel). Based on consumer and HCP demand research, the Company estimates that the accessible market for Arakoda represents about one third of this volume (about 330,000 prescriptions). Barriers to entry include low brand awareness in the prescriber community and the low cost of some of the generic alternatives. In the second half of 2024 we will conduct a pilot commercialization study to confirm these barriers can be overcome (see “Strategy”). Treatment and Prevention of Tick-Borne Disease (Babesiosis) We are repositioning the Arakoda regimen of Tafenoquine for several potential new therapeutic indications that have substantial U.S. caseloads, as further described below:

| ● | Treatment of Chronic                                                                                                                   
 Tick-Borne Disease (Babesiosis). Babesia parasites are co-transmitted by the same ticks that transmit Borrelia,                        
 the Lyme disease bacterium. Although Lyme in the acute phase is generally viewed by the medical community as being treatable with      
 antibiotics, individuals who are not treated, or fail treatment, may go on to develop long term, and potentially debilitating, chronic 
 symptoms such as fatigue, body aches, and cognitive problems.1 This condition is defined by the Centers for Disease Control            
 and Prevention (“CDC”) as Post-Treatment Lyme Disease Syndrome (“PTLDS”) or simply as Lyme in the patient                              
 community.2 Although there are no published estimates, key opinion leaders have stated that as many as 50% of Lyme/PTLDS               
 patients are believed to be co-infected with Babesia parasites, a diagnosis referred to in the Lyme community as “Chronic              
 Babesiosis.” Prescribers in the Lyme disease community utilize a number of therapeutic modalities to manage the symptoms of            
 Chronic Babesiosis, including FDA-approved pharmaceuticals such as atovaquone and azithromycin (these are assumed to suppress the      
 growth of Babesia parasites).3                                                                                                         |

| 1 | See https://www.cdc.gov/lyme/signs-symptoms/chron